Clinical Report: Dupilumab Gains Pediatric CSU Approval
Overview
Dupixent (dupilumab) has been approved by the FDA for pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine therapy, extending its prior indication in adolescents and adults.
Background
Chronic spontaneous urticaria is a type 2 inflammatory skin disease characterized by recurrent hives and pruritus that can severely impact the quality of life, particularly in children. The limited treatment options available for pediatric patients necessitate the development of new therapies, as current treatments often fail to provide adequate relief.
Data Highlights
The approval was supported by findings from the Phase 3 LIBERTY-CUPID clinical program, which included two randomized, placebo-controlled trials in patients aged 6 years and older, demonstrating significant reductions in itch severity and urticaria activity at 24 weeks, along with pharmacokinetic and safety data from a single-arm Phase 3 study in children aged 2 to 11 years.Key Findings
Dupilumab significantly reduced itch severity and overall urticaria activity compared to antihistamines alone. A higher proportion of patients achieved well-controlled disease or complete response with dupilumab. Safety outcomes were consistent with the established profile of dupilumab, with injection site reactions being the most common adverse events, occurring more frequently in patients receiving dupilumab compared to placebo. No new safety concerns were identified in pediatric patients aged 2 to 11 years.Clinical Implications
Healthcare providers now have a new treatment option for pediatric patients with CSU who do not respond adequately to antihistamines, potentially improving management strategies and enhancing the quality of life for affected children.
Conclusion
The FDA's approval of dupilumab for young children with CSU is a landmark development in pediatric dermatology, providing a much-needed therapeutic option for this challenging condition and paving the way for future biologic therapies.
References
- Sanofi, Press Release, 2025 -- Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
- Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials | Trials | JAMA Dermatology | JAMA Network, 2026
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria - PubMed, 2022
- The New Gastroenterologist — FDA Grants Approval for Simponi in Treating Pediatric Ulcerative Colitis
- The New Gastroenterologist — Mirikizumab demonstrates potential benefits for children suffering from ulcerative colitis
- The ASCO Post — Dinutuximab Combination Approved for Pediatric High-Risk Neuroblastoma
- The ASCO Post — Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria - PubMed
- Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials | Trials | JAMA Dermatology | JAMA Network
- Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
